TORONTO, CANADA — (May 30, 2019) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce its conference schedule for the upcoming months.
2019 BIO International Convention (June 3 – 6, 2019) – Philadelphia, United States
Antibe will be engaging in several days of one-on-one meetings with pharmaceutical companies to discuss licensing and partnering opportunities for Antibe’s lead drug, ATB-346. BIO International is the largest biopharma partnering event of the year, attracting over 16,000 leaders and business development executives from 5,000 companies across the globe.
9th Annual LD Micro Invitational (June 4 – 5, 2019) – Los Angeles, United States
Antibe’s CEO, Dan Legault, has been invited to present at the LD Micro investor conference on Tuesday, June 4th, 2019 at 9:40 am (Pacific Time) at the Luxe Hotel in Los Angeles, California. The LD Micro Invitational will feature 250 companies and will be attended by over 1,000 individuals.
European Congress of Rheumatology 2019 (June 12 – 15, 2019) – Madrid, Spain
Antibe’s Chief Scientific Officer, John Wallace, will be representing Antibe at Europe’s major conference for osteoarthritis organized by the European League Against Rheumatism (EULAR). EULAR promotes the translation of research advances into daily care and fights for the recognition of the needs of people with musculoskeletal diseases by the governing bodies in Europe.
TSX Venture 50 Capital Conference (July 11 – 13, 2019) – Kelowna, Canada
Antibe will be participating in the TSX Venture 50 Capital Conference, an investor networking event that includes one-on-one meetings exclusively for this year’s TSX Venture 50 winners. Antibe was ranked second in the Clean Technology and Life Sciences sector on the TSX Venture Exchange based on its performance last year.
In addition, the Company has amended its agreement with MKR Group, Inc. (“MKR”), a California-based investor relations firm, reflecting a monthly retainer of US$7,000 (per a revised agreement in 2018). MKR will continue to broaden awareness of Antibe amongst institutional investors and sell-side analysts in the United States. The engagement can be terminated by either party upon 30 days notice.
About Antibe Therapeutics Inc.
Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer drug for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a safer, non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. www.antibethera.com
Antibe’s subsidiary, Citagenix Inc. (“Citagenix”), is a leader in the sales and marketing of tissue regenerative products servicing the orthopedic and dental marketplaces. Since its inception in 1997, Citagenix has become an important source of knowledge and experience for bone regeneration in the Canadian medical device industry. Citagenix is active in 15 countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships. www.citagenix.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information
This news release includes certain forward-looking statements, which may include, but are not limited to, the growth of product sales, engaging new distributors and independent representatives, the completion of financing transactions and the licensing and development of drugs and medical devices. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “will”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “propose” and similar expressions. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Company’s ability to secure additional financing, its inability to execute its business strategy and successfully compete in the market, and risks associated with drug and medical device development generally. Antibe Therapeutics Inc. assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.
Contact Information
Antibe Therapeutics Inc.
Dan Legault
Chief Executive Officer
Tel: +1 416-473-4095
dan.legault@antibethera.com